Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

SMARCA4 and EZH2 are two functional key players of their respective antagonizing chromatin remodeling complexes SWI/SNF and PRC2. EZH2 inhibitory drugs may abrogate pro-oncogenic features of PRC2 and turn the balance to cell differentiation via SWI/SNF activity in cancers. SMARCA4 and EZH2 expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Leitner, Katharina, Tsibulak, Irina, Wieser, Verena, Knoll, Katharina, Reimer, Daniel, Marth, Christian, Fiegl, Heidi, Zeimet, Alain G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684284/
https://www.ncbi.nlm.nih.gov/pubmed/33230143
http://dx.doi.org/10.1038/s41598-020-77532-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684284/
https://www.ncbi.nlm.nih.gov/pubmed/33230143
http://dx.doi.org/10.1038/s41598-020-77532-x

Ejemplares similares